Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes

BACKGROUND: Brentuximab vedotin (BV) is a key therapeutic agent for patients with relapsed/refractory classical Hodgkin lymphoma (cHL). The outcomes of patients experiencing disease progression after BV are poorly described. PATIENTS AND METHODS: We reviewed our institutional database to identify pa...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Oncol
Autors principals: Cheah, C. Y., Chihara, D., Horowitz, S., Sevin, A., Oki, Y., Zhou, S., Fowler, N. H., Romaguera, J. E., Turturro, F., Hagemeister, F. B., Fayad, L. E., Wang, M., Neelapu, S. S., Nastoupil, L. J., Westin, J. R., Rodriguez, M. A., Samaniego, F., Anderlini, P., Nieto, Y., Fanale, M. A.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2016
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6357675/
https://ncbi.nlm.nih.gov/pubmed/27091808
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw169
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars